Treatment as prevention: The breaking of taboos is required in the fight against hepatitis C among people who inject drugs

Hepatology

Volumn 58, Issue 5, 2013, Pages 1523-1525

  Bruggmann, Philip ^a  

^a Arud Centres of Addiction Medicine   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; OPIATE; RIBAVIRIN;

AWARENESS; COST; DRUG INDUSTRY; DRUG USE; EDITORIAL; EPIDEMIC; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; INFECTION RISK; LIVER FIBROSIS; MATHEMATICAL MODEL; OPIATE SUBSTITUTION TREATMENT; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; REINFECTION; SCALE UP; TABOO; VULNERABLE POPULATION;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84887019380     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26539     Document Type: Editorial

References (5)

1. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58:1598-1609.
2. Nelson PK, Mathers BM, Cowie B, Hagan H, Des JD, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-583.
3. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012;55:49-57.
4. Bruggmann P. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat 2012;19:829-835.
5. The Global Commission on Drug Policy. The negative impact of the war on drugs on public health: the hidden hepatitis C epidemic. Available at: www.globalcommissionondrugs.org 2013 May 30. Accessed May 2013.